A New Orally Bioavailable Synthetic Androstene Inhibits Collagen‐Induced Arthritis in the Mouse
Authors:
- 27 September 2007
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1110 (1) , 630-640
Abstract
Dehydroepiandrosterone (DHEA) has attracted much interest because of its many antiaging, metabolic and immune‐modulating effects in rodents. Synthetic derivatives, such as 5‐androstene‐16α‐fluoro‐17‐one (HE2500) and certain natural metabolites also provide benefit in various animal models of autoimmune and metabolic diseases. But, like DHEA, low potency and low oral bioavailability suggested limited usefulness of these compounds in humans. We hypothesized that HE3286, a novel 17‐ethynyl derivative would be orally bioavailable, more potent, and chemically more useful in man than its parent compound. We found that on a dose/mass basis, HE3286 demonstrated up to 25% oral bioavailability in mice. In the DBA mouse model of collagen‐induced arthritis (CIA), animals receiving oral treatment with HE3286 (50 mg/kg), beginning at onset of disease, significantly decreased CIA peak scores and daily severity of arthritis scores. Benefit was associated with decreases in: (1) production of TNF‐α, IL‐6, and IL‐17; and (2) decreases in joint inflammation, erosion, and synovial proliferation as judged by histological analysis. HE3286 was not found to be immune suppressive in any of the classical models tested, including mitogen‐induced proliferation, delayed‐type hypersensitivity, or mixed lymphocyte reaction. Instead, benefit was associated with increases in numbers and function of CD4+CD25+FOXp3+CD127– regulatory T cells (Treg). To our knowledge, this is probably the first study to report that an orally bioavailable synthetic analogue of DHEA can ameliorate ongoing disease in a CIA mouse model with relevance to rheumatoid arthritis (RA) and to correlate that finding with decreases in proinflammatory cytokines and increases in Treg cells. Hormones targeting Treg cells hold the intriguing potential to treat autoimmune, infectious, and neoplastic diseases.Keywords
This publication has 35 references indexed in Scilit:
- Safety and Activity of the Immune Modulator HE2000 on the Incidence of Tuberculosis and Other Opportunistic Infections in AIDS PatientsAntimicrobial Agents and Chemotherapy, 2007
- Guarding the immune system: Suppression of autoimmunity by CD4+CD25+ immunoregulatory T cellsImmunology & Cell Biology, 2006
- Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathwayJournal of Neuroscience Research, 2006
- Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated miceJournal of Neuroimmunology, 2005
- 16α‐Bromoepiandrosterone Restores T Helper Cell Type 1 Activity and Accelerates Chemotherapy‐Induced Bacterial Clearance in a Model of Progressive Pulmonary TuberculosisThe Journal of Infectious Diseases, 2005
- A synthetic androstene analogue inhibits collagen-induced arthritis in the mouseClinical Immunology, 2004
- A Gender Gap in AutoimmunityScience, 1999
- Physiological importance of dehydroepiandrosteroneThe Lancet, 1994
- Androgenic Hormones Modulate Autoantibody Responses and Improve Survival in Murine LupusJournal of Clinical Investigation, 1977
- Systemic lupus erythematosus and pregnancy.BMJ, 1965